| News
BaseLaunch funds four healthcare ventures
05.02.2019
BaseLaunch supports carefully selected ventures in two phases. After an intense pressure test period, four projects were selected for Phase II of our second year. They now have the opportunity to further advance their breakthrough healthcare innovation and secure further investment.

BaseLaunch
The four healthcare ventures Anaveon, Pattern Biosciences, Synendos Therapeutics and a biotech in stealth mode receive funding of up to 250,000 Swiss francs as well as further support from BaseLaunch and its partners. Additionally, these projects have free-of-charge access to BaseLaunch’s co-working space and fully equipped shared laboratory in the Switzerland Innovation Park Basel Area in Allschwil.
This package allows the teams to focus on what truly matters: advancing and de-risking their science and further developing their ventures.
Applications for the BaseLaunch accelerator 2019 are now open
Further, BaseLaunch opens the next round of its accelerator program. The initiative, managed by BaselArea.swiss, is looking for people and projects with breakthrough healthcare innovations mainly in the field of therapeutics. However, applications are also open for game-changing innovation in diagnostics, medtech or related fields.
During Phase I, the selected projects develop their cases in Basel while having access to up to 10,000 Swiss francs each for consultancy and other services.
Phase II lasts at least twelve months, with each project receiving funding of up to 250,000 Swiss francs for further developing their venture.
Find out more about BaseLaunch and how to apply.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read MoreKUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read MoreBSI integrating AI from Parashift in banking software
Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...
Read MoreUptownBasel joins IBM Quantum Network
UptownBasel is partnering with IBM. The emerging competence center for Industry 4.0 will provide its partners with the IBM Quantum...
Read MoreSouth Korean pharma firms show interest in the Basel Area
Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...
Read More